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Prior studies on other inflammatory diseases such as
rheumatoid arthritis and systemic lupus erythematosus have
shown that the disease influences rates of preterm birth and
pregnancy loss.2 No statistically significant differences were
detected when comparing our study cohort with the general
population of women in the US in terms of the rates of mis-
carriage,3 C-section,4 premature baby,4 stillbirth5 and perinatal
mortality.5 In addition, baseline HS disease severity was not
significantly associated with poorer pregnancy or neonatal out-
comes. Thus, our findings on pregnancy outcomes can help
providers counsel and reassure concerned pregnant patients
with HS regarding pregnancy outcomes. In contrast, compared
with rates of gestational diabetes mellitus,6 gestational hyper-
tension7 and pre-eclampsia8 in the US general population, our
study cohort had a higher than average rate for each condi-
tion, with statistical significance detected for gestational hyper-
tension (P = 0022) and pre-eclampsia (P = 0017).
Therefore, screening for these conditions among pregnant
patients with HS is essential.
Study limitations include: that it took place at a single aca-
demic centre, was retrospective and contained missing data.
Lack of systematic follow-up of neonatal charts could have
resulted in underestimation of the perinatal mortality rate.
Only univariate analysis was conducted; thus, potential con-
founders have not been controlled for.
In summary, our study suggests that HS does not portend
an increased risk of poor pregnancy or neonatal outcomes.
Large, prospective pregnancy registries are needed to collect
data on maternal and neonatal outcomes in patients with
HS.
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Longer duration of lower-limb symptoms
makes cellulitis diagnosis less likely in
secondary care
DOI: 10.1111/bjd.19213
DEAR EDITOR, There is no evidence to support using an antibi-
otic for longer than 5 days in cellulitis.1 The National Institute
for Health and Care Excellence recommends specialist review
if cellulitis has not improved after 14 days despite antibiotics.2
The 2017 Cellulitis Priority Setting Partnership prioritized
research into diagnosis and treatment of cellulitis.3 Cellulitis
diagnosis is based on history, examination and inflammatory
markers. No validated diagnostic criteria or tools exist,4 and
up to 68% of people with suspected lower-limb cellulitis
(LLC) may not have the condition,5 leading to unnecessary
hospital admission and antibiotic treatment.6 Painful red legs
may also be caused by chronic conditions such as venous
eczema and lymphoedema, which are unresponsive to antibi-
otics.5 This study investigated whether (i) a shorter duration
of symptoms and (ii) a shorter duration of antibiotic treat-
ment predicted whether referred patients had LLC. Diagnosis
was defined clinically by experienced dermatologists.
This was a retrospective cohort study at a UK teaching hos-
pital with an outpatient-based service for suspected LLC.
Referral guidelines to the service included patients with severe
and/or nonresponsive suspected LLC. In total 106 consecutive
patients were assessed who were referred mostly from primary
care, and also from other hospital departments, between 3
January 2018 and 11 March 2019. The proportion with a final
diagnosis of LLC and other diagnoses was compared (v2-test)
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in (i) those with symptoms lasting 2 weeks or less at presen-
tation and (ii) those who had received antibiotics for less than
2 weeks at presentation.
Of the 106 referred patients; 36 (34%) had LLC, 31 (29%)
had venous eczema, 26 (25%) had lymphoedema and 13
(12%) had another diagnosis. Of those with LLC, 16 of 36
(44%) had concurrent lymphoedema and 10 of 36 (28%) had
concurrent venous eczema. In total 88 of 106 were eligible
for analysis on the duration of their symptoms, and 77 of 106
(73%) on the duration of antibiotics. Patients were excluded
if there was absence of data. Most of those excluded from
analysis (13 of 18 for duration of symptoms and 27 of 29 for
duration of antibiotics) did not have LLC. It is not thought
that this affected the findings.
The proportion with symptoms for < 14 days was signifi-
cantly greater in those with LLC than in those with other diag-
noses (Figure 1), v2 = 459, P < 0001. The proportion who
took antibiotics for < 14 days was not significantly greater in
patients with LLC than in patients with other diagnoses (Fig-
ure 1), v2 = 0001, P = 097.
This analysis shows that patients with LLC were more likely
to present acutely (within 14 days of symptom onset) compared
with patients with differential diagnoses causing red legs. There
is a recognized need to develop diagnostic criteria in LLC.4 This
study supports the duration of symptoms being incorporated
into future LLC diagnostic algorithms. By contrast, the duration
of antibiotics in people with red legs prior to being seen by a
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Figure 1 Durations of symptoms (top) and antibiotics (bottom) prior to assessment in patients with suspected lower-limb cellulitis (LLC) (grey),
patients with other diagnoses (orange) and patients with a confirmed diagnosis of LLC (blue).
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Late presentation was a marker that patients either did not
have cellulitis or also had lymphoedema or eczema as a
comorbidity to LLC. Patients with LLC may be categorized into
two broad clinical groups: firstly, patients with straightforward
LLC that responds to antibiotics, and secondly, a complex
group of patients with comorbid lymphoedema and eczema in
whom the diagnosis and treatment of LLC are more challeng-
ing. This latter group may benefit from early specialist input.
It has been shown that a shared-care approach between pri-
mary and secondary care improved early and accurate diagno-
sis and the avoidance of prolonged antibiotics.7
The participants represented a population from a specialist
service who were likely to have more complex disease. There-
fore the results may have reflected the referral pattern to sec-
ondary care. The proportion of all patients in primary care
being treated for cellulitis and eventually found not to have
cellulitis remains unclear, so these findings are applicable to
secondary care. It would be useful to validate this study in a
prospective primary care cohort, where patients may present
more acutely. However, this analysis is clinically useful
because this subset presents a common diagnostic and man-
agement challenge. This analysis assumed a correct diagnosis
from the service. Experienced dermatologists may have used
the duration of symptoms to help reach a diagnosis of LLC or
other diagnoses. If validated diagnostic criteria are developed
for LLC these could be utilized in future studies.
In conclusion, patients with a shorter history of symptoms
were more likely to have LLC rather than other diagnoses. The
duration of symptoms may help predict a diagnosis of LLC.
Patients with complex LLC with comorbid lymphoedema or
eczema could be referred to specialist services earlier to reduce
prolonged courses of antibiotics with no clinical improve-
ment.
K. Mistry iD and N.J. Levell iD
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Detection of genetic tumour predisposition
syndromes using electronic health records
DOI: 10.1111/bjd.19215
DEAR EDITOR, The restricted tumour repertoire of certain
genetic skin tumour syndromes, such as CYLD cutaneous
syndrome (CCS), is well recognized.1 Patients with CCS
develop multiple benign cylindromas and spiradenomas, a
presentation of skin appendageal tumours recognized to be
exclusively associated with loss of CYLD function.2 Conse-
quently, pathology coding records, which capture tumour-
level data, can be interrogated to detect patients who may
have undiagnosed CCS based on the presentation of multiple
CCS-specific tumours over time. We explored the feasibility
of this approach in a tertiary hospital serving a population of
3 million people, where a national genetic testing centre for
CCS was also based.
We interrogated the hospital pathology coding system,
using SNOMED codes and free-text searches to identify
patients with cutaneous cylindromas and spiradenomas pre-
senting over a 3-year period during which CYLD gene testing
data was available (2012–2015). Trichoepithelioma, seen in
some patients with CCS, was excluded, as the presentation of
multiple trichoepitheliomas may be associated with other
tumour syndromes such as naevoid basal cell carcinoma syn-
drome. During this period, 62 803 skin cases were identified,
of which 951 were appendageal tumours. Ninety-three cylin-
dromas, spiradenomas or tumours with histological features of
both were detected from 52 patients. We excluded patients
who presented with one tumour only (44 tumour specimens)
as these were more likely to be sporadic cases. We included
data for patients who had more than one tumour, or a combi-
nation of any of these lesions. This identified 14 patients with
49 tumour specimens. Electronic case note review was then
performed to determine whether these patients had undergone
CYLD testing according to the UK Gene Testing Network crite-
ria,3 or had been diagnosed on clinical grounds. The majority
(12 of 14 patients) had undergone dermatogenetic review and
gene testing and were confirmed to have CCS; however, two
did not appear to have a clinical diagnosis of CCS.
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